Adakveo® (crizanlizumab-tmca) helps prevent pain crises (called vaso-occlusive crises, or VOCs) in patients with sickle cell disease (SCD).
Vaso-occlusive crises occur when microcirculation is obstructed by “sickled” red blood cells. Adakveo works by binding to P-selectin, a protein that plays a central role in cellular interactions that can lead to vaso-occlusion. In its initial study, Adakveo was shown to reduce VOCs by about 45%.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.